Schott Pharma
4Q Revenues: $249 million (+4%)
FY Revenues: $1 billion (+7%)
Comments: The main driver of SCHOTT Pharma’s revenue growth in Q4 2024 was the strong year-end finish of the DDS segment. Revenues in the DDS segment reached $124 million, an increase of 12% yoy (at constant currencies: 11%). Q4 represented the highest quarterly revenue in this segment. This development was driven by the ongoing strong demand for prefillable syringes and, in particular, by good momentum in glass syringes. On a twelve-month basis, revenue in the DDS segment amounted to $461.3 million, an increase of 28% yoy (at constant currencies: 26%). Based on the good development in the DDS segment, which consists only of HVS products, the HVS revenue share increased by seven percentage points to 55%.
 
Meanwhile, in FY 2024, SCHOTT Pharma achieved strong revenue growth of 7% (at constant currencies: 12%). This growth was primarily fueled by the high demand for HVS products and SCHOTT Pharma’s continuous expansion of the corresponding capacities. 55% of revenue in FY 2024 came from strong-margin HVS, bringing the company closer to its mid-term target of above 60%.